Sarissa Consulting’s Turning Point Therapeutics TPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-12,000
Closed -$903K – 61
2022
Q2
$903K Buy
+12,000
New +$533K 1.28% 30

Sarissa Consulting's TPTX Position: Q3 2022 in Review

Sarissa Consulting sold out of Turning Point Therapeutics (TPTX) in Q3 2022, closing a stake of 12,000 shares — an estimated $903K sold.

Sarissa Consulting first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $903K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Sarissa Consulting reported no remaining Turning Point Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Sarissa Consulting sold 12,000 Turning Point Therapeutics shares in Q3 2022, an estimated $903K.
  • Sarissa Consulting first reported a position in Turning Point Therapeutics in Q2 2022 and held it in 1 quarter.
  • Sarissa Consulting's Turning Point Therapeutics position peaked at $903K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics as of Q3 2022.

Based on Sarissa Consulting's 13F filing for Q3 2022, filed 14 Nov 2022.